An Interventional Open-Label, Single-Dose, 4-Treatment, 4-Period Crossover Study to Evaluate the Relative Bioavailability of CTB and AVI Administered Via Various Tablets or Capsule Formulations of PF-07612577 (PF-06264006 [CTB] - PF-07338233 [AVP]) and the Effect of Food on the Bioavailability of CTB and AVI Administered Via Tablets in Healthy Adult Participants

The purpose of this study is to learn about the study medicine CTB-AVP for the treatment of severe urinary tract infections that require hospitalization.
This study is seeking for:
* adult male and female participants who are healthy and weigh more than 50 kg.
* participants who have normal blood pressure, normal kidney and liver function
* participants willing to stay away from caffeine and other medicines for the duration of the study.
Participants will be required to stay in the study clinic for two weeks. All participants in this study will receive study medicine CTB-AVP by mouth one time each day on four different days. Study medicine will be given in capsules or tablets, on an empty stomach or will be taken with a meal. The study will look at the experiences of people receiving the study medicine. This will help determine if the study medicine is safe and effective.

开始日期2024-07-29

申办/合作机构

Pfizer Inc.

NCT05554237

/ Completed临床1期

A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, SINGLE AND MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-07612577 (PF-06264006 [CTB] + PF-07338233 [AVP]) IN HEALTHY ADULT PARTICIPANTS

The purpose of this clinical trial is to learn about the pharmacokinetics, safety and tolerability of various single- and multiple-doses of CTB+AVP in healthy adult participants. CTB+AVP is a study medicine that is being developed to treat people with complicated urinary tract infections.
This study is seeking healthy adult male and female participants, 18-60 years of age, with a body weight > 50 kg and a BMI of 17.5 to 30.5 kg/m2.
Participants in Part-1 of the study will receive increasing single doses of CTB and/or AVP. Participants in Part-2 will receive increasing multiple doses of CTB+AVP three times a day for 7 days. The study team will monitor how each participant is doing with the study treatments via close monitoring in an in-patient setting. Experiences of people receiving CTB+AVP will be compared to those of people who do not. This will help determine if CTB+AVP is safe and well-tolerated at each dose of the study medicine.
Participants will take part in this study for a maximum of 12 weeks for Part-1 (up to 4 weeks for screening, up to 3 weeks of taking study medicine and up to 5 weeks for safety follow-up visit) and for a maximum of 10 weeks for Part-2 (up to 4 weeks for screening, up to 1 week of taking study medicine and up to 5 weeks for safety follow-up visit). During the duration of the study, blood samples for study medicine levels, and various measures for monitoring safety such as blood samples for clinical laboratory measurements, electrocardiograms and vital sign measurements will be taken.

开始日期2022-10-07

申办/合作机构

Pfizer Inc.

100 项与 Avibactam Tomilopil 相关的临床结果

登录后查看更多信息

100 项与 Avibactam Tomilopil 相关的转化医学

登录后查看更多信息

100 项与 Avibactam Tomilopil 相关的专利（医药）

登录后查看更多信息

项与 Avibactam Tomilopil 相关的文献（医药）

2018-11-21·Journal of Medicinal Chemistry1区 · 医学

Orally Absorbed Derivatives of the β-Lactamase Inhibitor Avibactam. Design of Novel Prodrugs of Sulfate Containing Drugs

1区 · 医学

Article

作者: Duncton, Matthew A. J. ; Gallop, Mark A. ; Gordon, Eric M.

Only one FDA-approved β-lactamase inhibitor has ever been orally available: clavulanic acid, approved in 1984. Avibactam, approved by FDA in 2015, is the first of a new class of BLIs called diazabicyclooctanes, or "DBOs". This class has much broader coverage than clavulanic acid but can only be administered by intravenous injection. Herein, we describe the synthesis and testing of the first approved BLI to be rendered orally bioavailable since clavulanic acid (1984).

100 项与 Avibactam Tomilopil 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
复杂的尿路感染	临床1期	比利时	Pfizer Inc.	2022-09-23

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASN2020	N/A	-	43	AVP use post DDKT	窪夢艱窪遞壓蓋餘簾製(範網廠醖觸廠廠壓鏇膚) = 鹽觸廠憲襯繭選網構鹽遞糧壓壓鹹積顧選夢積 (廠淵餘獵夢廠鹽顧繭衊 ) 更多	积极	2020-10-19
ARVO2015	N/A	-	-	PBS	積醖壓襯鹽艱夢夢艱齋(艱蓋鹽醖範網憲廠遞構) = 醖願範淵製選簾夢願鑰糧廠齋網鹹廠膚夢蓋壓 (窪製網鹹顧顧齋鑰淵窪 )	-	2015-06-01
				AVP	積醖壓襯鹽艱夢夢艱齋(艱蓋鹽醖範網憲廠遞構) = 蓋憲構鏇鏇艱鬱淵構顧糧廠齋網鹹廠膚夢蓋壓 (窪製網鹹顧顧齋鑰淵窪 )
AAN2014	临床3期	急性偏头痛	223	AVP-825 22 mg	窪構簾鑰簾醖獵齋顧餘(鑰糧糧鹽蓋簾鹽憲淵範) = 憲選鑰廠鏇構鹹繭淵膚窪構鹹醖製鏇廠衊窪鏇 (願糧鏇憲網積淵憲築築 ) 更多	积极	2014-04-08
				Placebo	窪構簾鑰簾醖獵齋顧餘(鑰糧糧鹽蓋簾鹽憲淵範) = 築遞襯醖廠夢獵鏇觸構窪構鹹醖製鏇廠衊窪鏇 (願糧鏇憲網積淵憲築築 ) 更多